Has anyone else..


anonymous

Guest
Experienced this at another company where certain parts of the country have a clear advantage and leadership just turns a blind eye and says “it is what it is”. I’m new to pharma but this is absolutely outrageous. The Medicaid states are advantaged to a degree that is so incredibly unreasonable. I do reasonably understand that not all territories will always be equal yes that is a reasonable argument, however, this level of advantage is alarming and truly sets the rest of us at an extreme disadvantage. The numbers the Medicaid reps are acquiring are clear outliers and omitting it is disappointing to all of us newbies to see. It sounds like the more tenured reps are really frustrated with the company and the newer reps are starting to see why.
 








Experienced this at another company where certain parts of the country have a clear advantage and leadership just turns a blind eye and says “it is what it is”. I’m new to pharma but this is absolutely outrageous. The Medicaid states are advantaged to a degree that is so incredibly unreasonable. I do reasonably understand that not all territories will always be equal yes that is a reasonable argument, however, this level of advantage is alarming and truly sets the rest of us at an extreme disadvantage. The numbers the Medicaid reps are acquiring are clear outliers and omitting it is disappointing to all of us newbies to see. It sounds like the more tenured reps are really frustrated with the company and the newer reps are starting to see why.
You sell a skin cream in a generic world. It’s not that deep. This is a life saving drug. Move on.
 
























you sound like the kind who loved participation medals
I would love to compete with you at anything and it's people like you who make my job easy
The only thing that makes your job easy is your geography you old fuck. Can’t wait to go to goals so all you privileged Medicaid duck suckers can be humbled.
 








Arcutis Biotherapeutics (NASDAQ:ARQT) rose 12% amid some takeover speculation.

The biotech is speculated to have attracted some takeover interest, according to traders, who cited a Betaville "uncooked" alert that circulated on Wednesday. An unidentified European company is said to be interested.

Bye bye Kowa
 








Arcutis Biotherapeutics (NASDAQ:ARQT) rose 12% amid some takeover speculation.

The biotech is speculated to have attracted some takeover interest, according to traders, who cited a Betaville "uncooked" alert that circulated on Wednesday. An unidentified European company is said to be interested.


Bye bye Kowa